AnaptysBio Valuation
| ANAB Stock | USD 49.73 1.83 3.82% |
At this time, the firm appears to be undervalued. AnaptysBio shows a prevailing Real Value of $53.22 per share. The current price of the firm is $49.73. Our model approximates the value of AnaptysBio from analyzing the firm fundamentals such as profit margin of (0.50) %, and Return On Equity of -3.08 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AnaptysBio's valuation include:
Price Book 114.7281 | Enterprise Value | Enterprise Value Ebitda (1.30) | Price Sales 8.2087 | Enterprise Value Revenue 6.7358 |
Undervalued
Today
Please note that AnaptysBio's price fluctuation is very steady at this time. Calculation of the real value of AnaptysBio is based on 3 months time horizon. Increasing AnaptysBio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AnaptysBio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AnaptysBio Stock. However, AnaptysBio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 49.73 | Real 53.22 | Target 67.92 | Hype 49.43 |
The real value of AnaptysBio Stock, also known as its intrinsic value, is the underlying worth of AnaptysBio Company, which is reflected in its stock price. It is based on AnaptysBio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of AnaptysBio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of AnaptysBio helps investors to forecast how AnaptysBio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AnaptysBio more accurately as focusing exclusively on AnaptysBio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AnaptysBio's intrinsic value based on its ongoing forecasts of AnaptysBio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AnaptysBio's closest peers. If more than one evaluation category is relevant for AnaptysBio we suggest using both methods to arrive at a better estimate.
AnaptysBio Cash |
|
AnaptysBio Total Value Analysis
AnaptysBio is presently forecasted to have valuation of 1.14 B with market capitalization of 1.39 B, debt of 369.46 M, and cash on hands of 442.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the AnaptysBio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.14 B | 1.39 B | 369.46 M | 442.15 M |
AnaptysBio Investor Information
About 94.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.82. AnaptysBio had not issued any dividends in recent years. Based on the analysis of AnaptysBio's profitability, liquidity, and operating efficiency, AnaptysBio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.AnaptysBio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AnaptysBio has an asset utilization ratio of 18.87 percent. This suggests that the Company is making $0.19 for each dollar of assets. An increasing asset utilization means that AnaptysBio is more efficient with each dollar of assets it utilizes for everyday operations.AnaptysBio Profitability Analysis
Considering AnaptysBio's profitability and operating efficiency indicators, AnaptysBio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess AnaptysBio's ability to earn profits and add value for shareholders.Net Loss | First Reported 2013-12-31 | Previous Quarter -38.6 M | Current Value 15.1 M | Quarterly Volatility 17.7 M |
For AnaptysBio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of AnaptysBio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well AnaptysBio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between AnaptysBio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of AnaptysBio over time as well as its relative position and ranking within its peers.
AnaptysBio Earnings per Share Projection vs Actual
The next projected EPS of AnaptysBio is estimated to be -1.02505 with future projections ranging from a low of -1.9575 to a high of 0.27565. AnaptysBio's most recent 12-month trailing earnings per share (EPS TTM) is at -2.82. Please be aware that the consensus of earnings estimates for AnaptysBio is based on EPS before non-recurring items and includes expenses related to employee stock options.AnaptysBio Earnings Estimation Breakdown
The calculation of AnaptysBio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of AnaptysBio is estimated to be -1.02505 with the future projection ranging from a low of -1.9575 to a high of 0.27565. Please be aware that this consensus of annual earnings estimates for AnaptysBio is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.96 Lowest | Expected EPS | 0.28 Highest |
AnaptysBio Earnings Projection Consensus
Suppose the current estimates of AnaptysBio's value are higher than the current market price of the AnaptysBio stock. In this case, investors may conclude that AnaptysBio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and AnaptysBio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 13 | 66.18% | 0.0 | -1.02505 | -2.82 |
AnaptysBio Ownership Allocation
The majority of AnaptysBio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AnaptysBio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AnaptysBio. Please pay attention to any change in the institutional holdings of AnaptysBio as this could imply that something significant has changed or is about to change at the company.AnaptysBio Profitability Analysis
The company reported the previous year's revenue of 91.28 M. Net Loss for the year was (145.23 M) with profit before overhead, payroll, taxes, and interest of 16.47 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates AnaptysBio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in AnaptysBio and how it compares across the competition.
About AnaptysBio Valuation
The stock valuation mechanism determines AnaptysBio's current worth on a weekly basis. Our valuation model uses a comparative analysis of AnaptysBio. We calculate exposure to AnaptysBio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AnaptysBio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -65.3 M | -62 M | |
| Pretax Profit Margin | (1.83) | (1.92) | |
| Operating Profit Margin | (1.45) | (1.52) | |
| Net Loss | (1.83) | (1.92) | |
| Gross Profit Margin | (0.91) | (0.96) |
AnaptysBio Current Valuation Indicators
Valuation refers to the process of determining the present value of AnaptysBio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value AnaptysBio we look at many different elements of the entity such as AnaptysBio's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AnaptysBio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AnaptysBio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AnaptysBio's worth.Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |